VBIV VBI Vaccines
- 0.603
- +0.003+0.55%
VBI Vaccines News
VBI Vaccines FY Non-GAAP EPS of $3.96
VBI Vaccines Soars With Hepatitis B Vaccine Success
VBI Vaccines 2023 Rev $8.7M >VBIV
VBI Vaccines 2023 Rev $8.7M >VBIV
VBI Vaccines Raises $1.7 Million in Direct Share Offering
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously announced registered
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
VBI Vaccines Shares Are Trading Lower After the Company Announced a $2 Million Registered Direct Offering at $0.88 per Share.
VBI Vaccines Shares Are Trading Lower After the Company Announced a $2 Million Registered Direct Offering at $0.88 per Share.
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into definitive agreements for
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ:BPTS) rose sharply in today's pre-market trading after reporting FY23 results. Biophytis posted a FY23 loss of €0.03 per share, versus a year-ago loss of €0.14 per s
VBI Vaccines Inc Release: Content Unintelligible
VBI Vaccines to Present Early Phase 2b Cancer Vaccine Results
VBI Vaccines Bolsters Collaboration With Canadian Government
VBI Vaccines Expands Collaboration With Canadian Government; Says Under The New Agreement, The Remaining C$28M Of Funding Available Under The Previously Committed C$56M Will Be Directed Toward The Development Of VBI's MLE Platform
VBI Vaccines Expands Collaboration With Canadian Government; Says Under The New Agreement, The Remaining C$28M Of Funding Available Under The Previously Committed C$56M Will Be Directed Toward The Dev
VBI Vaccines To Expand Strategic Partnership With Canadian Government; Partnership To Direct CAD$28M Of Funding Remaining Under Original CAD$56M Award To Continue Development Of Proprietary Tech Platforms
VBI Vaccines To Expand Strategic Partnership With Canadian Government; Partnership To Direct CAD$28M Of Funding Remaining Under Original CAD$56M Award To Continue Development Of Proprietary Tech Platf
Strategic Licensing Agreements: Brii Bio's Expansion Into Chronic Disease Treatments With VBI Vaccines
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences
VBI Vaccines (VBIV) on Wednesday announced the sale of the intellectual property rights to its hepatitis B vaccine candidate to Brii Biosciences for up to $33 million. Under the agreement, Brii will r
VBI Signs Deal to Sell Manufacturing Capabilities, Certain Assets With Brii Biosciences
VBI Vaccines Advances Strategy With Key Financial Moves
VBI Vaccines: Received $2.5 M of Consideration Upon Signing of Definitive Documents and Expect to Receive Up to an Additional $30.5M of Consideration, Subject to Achievement of Certain Activities, With a Target Completion Date of June 30 >VBIV
VBI Vaccines: Received $2.5 M of Consideration Upon Signing of Definitive Documents and Expect to Receive Up to an Additional $30.5M of Consideration, Subject to Achievement of Certain Activities, Wit
Brii Biosciences Agrees To Acquire VBI's IP Rights In BRII-179 (VBI-2601) And Plans To Initiate Technology Transfer To Expand Clinical And Commercial Supplies
Under these agreements, Brii Bio will issue a $2.5 million promissory note to VBI initially. This will eliminate royalty and milestone payments for PreHevbri. Upon meeting specific conditions, the not
Analysis
Price Target
No Data
